Companies penetrating these markets often acquire local manufacturers and generics firms that provide a quick, cost-effective point of entry from which to later launch more expensive branded products. However, some Asia-Pacific countries are introducing or considering measures to protect the domestic industries from foreign domination.
Within the period analyzed in this report, the highest number of M&A deals involving APAC based companies was recorded in 2008. Strong recovery from the global financial crisis can be seen in late 2009. Furthermore, 2010 seems to be off to a good start, with a number of large deals involving APAC-based companies having been announced.
Reasons to Purchase*Gain insight into the number and Scope of M&A transactions in Asia-Pacific, and key drivers and resistors.
*Identify which are the most perused pharmaceutical sectors in terms of M&A deals, and which companies have been the most acquisitive in recent years.
*Identify which markets have been most frequently targeted through M&As, and which have attracted the attention of Big Pharma.
ABOUT DATAMONITOR HEALTHCARE 2
About the Healthcare Strategic Analysis Team 2
Geographic specific reports: 2
Global issue reports: 2
About the Healthcare Asia-Pacific Team 3
1. Executive Summary 4
Strategic scoping and focus 4
Key findings 5
Key definitions 6
Company classifications 6
Acquisition types 6
Geographic classifications 7
Related reports 8
Upcoming related reports 8
TABLE OF CONTENTS 9
2. Overview of the APAC pharmaceutical markets 10
Key findings 10
Gaining government drug reimbursement is the key to success in Australia 12
Government participation in healthcare 12
Key health concerns 12
Pharmaceutical market structure 13
Chinese healthcare r
Copyright©2010 PR Newswire.
All rights reserved